Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Glycobiology
2021 Nov 18;3110:1319-1329. doi: 10.1093/glycob/cwab066.
Show Gene links
Show Anatomy links
Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts.
Maccarana M
,
Tykesson E
,
Pera EM
,
Gouignard N
,
Fang J
,
Malmström A
,
Ghiselli G
,
Li JP
.
???displayArticle.abstract???
Mucopolysaccharidosis type I (MPS-I) is a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-L-iduronidase, which removes iduronic acid in both chondroitin/dermatan sulfate (CS/DS) and heparan sulfate (HS) and thereby contributes to the catabolism of glycosaminoglycans (GAGs). To ameliorate this genetic defect, the patients are currently treated by enzyme replacement and bone marrow transplantation, which have a number of drawbacks. This study was designed to develop an alternative treatment by inhibition of iduronic acid formation. By screening the Prestwick drug library, we identified ebselen as a potent inhibitor of enzymes that produce iduronic acid in CS/DS and HS. Ebselen efficiently inhibited iduronic acid formation during CS/DS synthesis in cultured fibroblasts. Treatment of MPS-I fibroblasts with ebselen not only reduced accumulation of CS/DS but also promoted GAG degradation. In early Xenopus embryos, this drug phenocopied the effect of downregulation of DS-epimerase 1, the main enzyme responsible for iduronic production in CS/DS, suggesting that ebselen inhibits iduronic acid production in vivo. However, ebselen failed to ameliorate the CS/DS and GAG burden in MPS-I mice. Nevertheless, the results propose a potential of iduronic acid substrate reduction therapy for MPS-I patients.
Azad,
Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.
2014, Pubmed
Azad,
Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways.
2014,
Pubmed
Banecka-Majkutewicz,
Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
2012,
Pubmed
Bartolini,
Iduronic acid in chondroitin/dermatan sulfate affects directional migration of aortic smooth muscle cells.
2013,
Pubmed
Campbell,
Biosynthesis of heparin/heparan sulfate. Purification of the D-glucuronyl C-5 epimerase from bovine liver.
1994,
Pubmed
Chen,
Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
2019,
Pubmed
Clarke,
The mucopolysaccharidoses: a success of molecular medicine.
2008,
Pubmed
Clarke,
Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
1997,
Pubmed
Coutinho,
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.
2016,
Pubmed
Derrick-Roberts,
Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice.
2017,
Pubmed
Gouignard,
Musculocontractural Ehlers-Danlos syndrome and neurocristopathies: dermatan sulfate is required for Xenopus neural crest cells to migrate and adhere to fibronectin.
2016,
Pubmed
,
Xenbase
Gouignard,
Gene expression of the two developmentally regulated dermatan sulfate epimerases in the Xenopus embryo.
2018,
Pubmed
,
Xenbase
Hagner-Mcwhirter,
Biosynthesis of heparin/heparan sulphate: mechanism of epimerization of glucuronyl C-5.
2000,
Pubmed
Hampe,
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.
2020,
Pubmed
Hannesson,
Biosynthesis of dermatan sulphate. Defructosylated Escherichia coli K4 capsular polysaccharide as a substrate for the D-glucuronyl C-5 epimerase, and an indication of a two-base reaction mechanism.
1996,
Pubmed
Hasan,
The structure of human dermatan sulfate epimerase 1 emphasizes the importance of C5-epimerization of glucuronic acid in higher organisms.
2021,
Pubmed
Kil,
Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.
2017,
Pubmed
Kosho,
CHST14/D4ST1 deficiency: New form of Ehlers-Danlos syndrome.
2016,
Pubmed
Kubaski,
Mucopolysaccharidosis Type I.
2020,
Pubmed
Lamanna,
A genetic model of substrate reduction therapy for mucopolysaccharidosis.
2012,
Pubmed
Maccarana,
Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is identical to SART2.
2006,
Pubmed
Maccarana,
Dermatan sulfate epimerase 1-deficient mice have reduced content and changed distribution of iduronic acids in dermatan sulfate and an altered collagen structure in skin.
2009,
Pubmed
Malmström,
Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function.
2012,
Pubmed
Mayor,
The neural crest.
2013,
Pubmed
,
Xenbase
Mikami,
Specificities of three distinct human chondroitin/dermatan N-acetylgalactosamine 4-O-sulfotransferases demonstrated using partially desulfated dermatan sulfate as an acceptor: implication of differential roles in dermatan sulfate biosynthesis.
2003,
Pubmed
Ou,
Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics.
2014,
Pubmed
Owens,
Metabolism and turnover of cell surface-associated heparan sulfate proteoglycan and chondroitin sulfate proteoglycan in normal and cholesterol-enriched macrophages.
1991,
Pubmed
Petersen,
Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4.
1999,
Pubmed
Pikas,
Substrate specificity of heparanases from human hepatoma and platelets.
1998,
Pubmed
Préchoux,
C5-epimerase and 2-O-sulfotransferase associate in vitro to generate contiguous epimerized and 2-O-sulfated heparan sulfate domains.
2015,
Pubmed
Sies,
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
2020,
Pubmed
Stachtea,
Dermatan Sulfate-Free Mice Display Embryological Defects and Are Neonatal Lethal Despite Normal Lymphoid and Non-Lymphoid Organogenesis.
2015,
Pubmed
Tucker,
Independent induction and formation of the dorsal and ventral fins in Xenopus laevis.
2004,
Pubmed
,
Xenbase
Tykesson,
Dermatan sulfate epimerase 1 and dermatan 4-O-sulfotransferase 1 form complexes that generate long epimerized 4-O-sulfated blocks.
2018,
Pubmed
Tykesson,
Deciphering the Mode of Action of the Processive Polysaccharide Modifying Enzyme Dermatan Sulfate Epimerase 1 by Hydrogen-Deuterium Exchange Mass Spectrometry.
2016,
Pubmed
Wlad,
Biosynthesis of heparin. Different molecular forms of O-sulfotransferases.
1994,
Pubmed
